CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 for Body Recomp Stack Research — Protocol Design

Real Peptides Research TeamEditorial

Updated April 22, 20268 min read

60 WORDS

Short answer

Key takeaways

CJC-1295 with DAC extends growth hormone pulse amplitude for 5–7 days per injection, producing mean IGF-1 increases of 45–60% above baseline in clinical trials.
Recomposition requires maintenance-level calories or modest deficit (10–15%) paired with 1.6–2.2g protein per kilogram bodyweight distributed across meals at the leucine threshold (2.5–3g leucine per meal).
Dosing protocols in published research use 30–60mcg/kg weekly subcutaneously, with 30–45mcg/kg balancing efficacy and tolerability for body composition applications.
The peptide's half-life of 146–165 hours means timing relative to training or meals has minimal impact. Consistency matters more than acute post-injection windows.
Temperature-sensitive storage (2–8°C after reconstitution, −20°C for lyophilised powder) is critical. Degradation from heat exposure is irreversible and undetectable by appearance.
Observable body composition changes typically require 8–12 weeks of consistent dosing paired with structured resistance training. Faster timelines reflect unrealistic expectations.

Researchers investigating body recomposition protocols encounter a persistent problem: growth hormone secretagogues offer theoretical benefits for simultaneous fat loss and lean mass preservation, but most compounds require daily dosing and produce highly variable serum GH levels. CJC-1295 with DAC (Drug Affinity Complex) addresses this through a modified structure that extends biological half-life to approximately 6–8 days, allowing once-weekly administration while maintaining elevated baseline growth hormone levels. Published trials from the Journal of Clinical Endocrinology & Metabolism demonstrate mean serum IGF-1 increases of 60% above baseline at 30mcg/kg dosing, sustained across the full seven-day inter-dose interval. A pharmacokinetic profile no natural secretagogue achieves.

Our team has analysed hundreds of recomposition research protocols combining CJC-1295 with dietary interventions and resistance training frameworks. The difference between protocols that produce measurable body composition changes and those that don't comes down to three factors most supplement guides never address: precise caloric positioning relative to maintenance, leucine-threshold protein distribution across meals, and realistic timeline expectations for observable fat-to-muscle ratio shifts.

What makes CJC-1295 effective for body recomposition research?

CJC-1295 binds to endogenous GHRH (growth hormone-releasing hormone) receptors in the anterior pituitary, amplifying the body's natural pulsatile GH secretion rather than replacing it. The DAC modification extends plasma half-life from minutes to days, creating sustained elevation of baseline GH and downstream IGF-1 without the sharp peaks and troughs seen with unmodified peptides. This produces mean IGF-1 increases of 45–60% that persist throughout the weekly dosing cycle, supporting lipolysis and nitrogen retention simultaneously.

The Biological Mechanism Behind CJC-1295 in Recomposition Protocols

CJC-1295's recomposition potential stems from its action as a GHRH analog with extended pharmacokinetics. Where native GHRH has a plasma half-life under 10 minutes, the DAC modification. A chemical linker that binds to serum albumin. Extends CJC-1295's half-life to 146–165 hours in human trials. This means a single subcutaneous injection maintains elevated GH pulse amplitude for 5–7 days, creating a hormonal environment that supports both lipolysis (via hormone-sensitive lipase activation in adipocytes) and protein synthesis (via IGF-1-mediated mTOR signalling in muscle tissue).

The mechanism is indirect but measurable. Growth hormone itself binds to GH receptors on hepatocytes, triggering IGF-1 synthesis. The primary mediator of anabolic effects. Simultaneously, GH acts directly on adipose tissue to increase lipolysis, mobilising free fatty acids for oxidation. The elevation is modest compared to exogenous GH administration. Trial data shows mean IGF-1 increases of 60% versus 200–300% with recombinant growth hormone. But the risk profile differs substantially. CJC-1295 works within physiological feedback loops; pituitary GH secretion still responds to somatostatin inhibition, preventing the supraphysiological peaks that cause insulin resistance and joint oedema.

Research published in Growth Hormone & IGF Research found that CJC-1295 at 30mcg/kg weekly produced statistically significant reductions in trunk fat mass (−2.1kg mean) and increases in lean mass (+1.4kg mean) over 12 weeks in middle-aged adults maintaining isocaloric intake. The effect size was modest but consistent. Body recomposition at maintenance calories, not aggressive weight loss. This aligns with GH's known metabolic actions: it shifts substrate utilisation toward fat oxidation while preserving lean tissue during energy restriction.

Stacking CJC-1295: Synergistic Compounds and Nutrition Protocols

CJC-1295 for body recomp stack research typically pairs the peptide with compounds that address complementary pathways. The most evidence-supported combinations involve ghrelin mimetics (like MK 677) or selective androgen receptor modulators in research contexts, but the nutritional framework matters more than peptide selection. GH elevation without adequate protein intake and resistance stimulus produces minimal lean mass accretion. The hormone creates permissive conditions for recomposition, not guaranteed outcomes.

Protein distribution is the single most overlooked variable in recomposition protocols. Research from the American Journal of Clinical Nutrition established the leucine threshold. Approximately 2.5–3g leucine per meal. Required to maximally stimulate muscle protein synthesis via mTOR activation. For most individuals, this translates to 25–40g complete protein per meal, distributed across 3–4 feeding windows. GLP-1-mediated appetite suppression (common in stacked protocols) makes hitting 1.6–2.2g protein per kilogram bodyweight significantly harder, which undermines the anabolic environment CJC-1295 creates. We've found that clients who track per-meal leucine content alongside total daily protein consistently show superior lean mass retention during caloric deficits.

Caloric positioning determines whether CJC-1295 drives fat loss, lean gain, or simultaneous recomposition. At 10–15% deficit, the peptide's lipolytic effects dominate. Subjects lose fat while GH's anti-catabolic properties preserve muscle. At maintenance, true recomposition occurs: fat oxidation increases while protein synthesis remains elevated, producing gradual body composition shifts without scale weight change. At surplus, lean mass accrual accelerates, but fat gain is not eliminated. The peptide amplifies existing metabolic conditions; it doesn't override thermodynamics.

Dosing Protocols and Administration Timing for CJC-1295

Research-grade CJC-1295 dosing in human trials has ranged from 30mcg/kg to 60mcg/kg administered subcutaneously once weekly. For a 75kg individual, this translates to approximately 2.25mg per injection. The dose-response curve shows diminishing returns above 60mcg/kg. Higher doses produce marginal additional IGF-1 elevation but increase the incidence of transient side effects like injection site reactions and mild water retention. Most published recomposition protocols use the lower end (30–45mcg/kg weekly) to balance efficacy with tolerability.

Timing relative to training and feeding windows is frequently debated but lacks strong empirical support. CJC-1295's extended half-life means plasma concentrations remain relatively stable across the week. There is no acute post-injection GH spike that benefits from specific nutrient timing. Some researchers prefer evening administration to align with natural nocturnal GH pulses, but controlled trials show no significant difference in IGF-1 response between morning and evening dosing. Consistency matters more than timing.

Reconstitution requires bacteriostatic water at a 1:1 or 2:1 ratio (2mg peptide in 1–2mL water), with the solution refrigerated at 2–8°C and used within 28 days. Lyophilised powder should be stored at −20°C before reconstitution. Temperature excursions above 8°C after mixing cause irreversible protein denaturation. A single overnight mistake renders the peptide inactive, though visual inspection won't reveal degradation. Real Peptides' commitment to high-purity synthesis ensures starting material integrity, but handling post-delivery is entirely user-controlled.

CJC-1295 for Body Recomp Stack Research: Protocol Comparison

The table below compares three common CJC-1295 research stacking approaches, detailing target outcomes, typical adjunct compounds, and realistic timelines for observable body composition changes.

Protocol Type	Primary Mechanism	Typical Adjuncts	Expected Timeline	Professional Assessment
Pure CJC-1295 Monotherapy	GHRH receptor agonism → sustained GH/IGF-1 elevation	None (peptide-only baseline)	8–12 weeks for measurable recomp	Best for isolating CJC-1295 effects; slower than stacked protocols but clearer attribution
CJC-1295 + Ghrelin Mimetic	Dual-pathway GH stimulation (GHRH + ghrelin receptors)	MK-677 or GHRP-6	6–10 weeks for lean mass gain + fat loss	Synergistic GH pulse amplitude; higher appetite may complicate deficit adherence
CJC-1295 + Caloric Cycling	GH elevation during refeed phases to preserve muscle	Structured refeeds 1–2x/week	10–16 weeks for significant recomp	Ideal for advanced subjects; requires precise macronutrient tracking and training periodisation

What If: CJC-1295 Body Recomp Scenarios

What If I Don't See Scale Weight Change After 6 Weeks on CJC-1295?

Maintain the protocol. True recomposition produces simultaneous fat loss and lean mass gain, which can leave total bodyweight unchanged while body composition shifts measurably. Track waist circumference, progress photos, and performance metrics (strength, endurance) instead of scale weight. If caloric intake is at maintenance and protein distribution meets leucine thresholds, absence of weight change alongside improved body composition is the expected outcome, not a failure. Adjust only if circumference measurements and visual assessment show no change after 10–12 weeks.

What If I Experience Persistent Water Retention on CJC-1295?

Reduce sodium intake to 2,000–2,500mg daily and assess hydration status. GH elevation increases aldosterone sensitivity, which promotes sodium retention and extracellular water accumulation. If retention persists beyond two weeks at stable dosing, consider lowering the dose to 30mcg/kg or implementing a natural diuretic like dandelion root extract. Severe or sudden-onset oedema warrants discontinuation and medical evaluation. This is rare with CJC-1295 but possible at higher doses.

What If I Miss a Weekly CJC-1295 Injection by Three Days?

Administer the missed dose as soon as you remember if fewer than four days have passed since the scheduled injection, then resume your regular weekly schedule from that new administration date. If more than four days late, skip the missed dose and continue with your next scheduled injection to avoid overlapping elevated GH periods. Missing a single dose creates a temporary dip in IGF-1 levels but doesn't erase prior progress. Recomposition timelines simply extend by the duration of the gap.

The Unglamorous Truth About CJC-1295 and Body Recomposition

Here's the honest answer: CJC-1295 for body recomp stack research won't produce dramatic physique changes in isolation. The peptide creates a modestly elevated anabolic environment. 60% higher IGF-1 is meaningful but not transformative without the right nutritional and training inputs. Subjects who expect visible results within four weeks are misunderstanding the mechanism entirely. Growth hormone's effects on body composition are gradual and conditional: it shifts substrate utilisation toward fat oxidation and supports nitrogen retention, but it doesn't override caloric balance or compensate for inadequate protein intake.

The marketing surrounding GH secretagogues consistently overstates acute effects. Clinical trial data shows mean fat loss of 2–3kg and lean mass gain of 1–2kg over 12–16 weeks at maintenance calories. Respectable outcomes, but nowhere near the

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 with DAC has a plasma half-life of 146–165 hours (approximately 6–8 days), meaning a single subcutaneous injection maintains elevated growth hormone pulse amplitude and IGF-1 levels for 5–7 days. This extended pharmacokinetic profile allows once-weekly dosing while sustaining mean IGF-1 increases of 45–60% above baseline throughout the inter-dose interval — a significant advantage over unmodified GHRH analogs that require daily administration.

CJC-1295 increases lipolysis through growth hormone’s direct action on adipose tissue, but meaningful fat loss requires caloric deficit or maintenance-level intake paired with increased energy expenditure. Clinical trials show modest fat reduction (1–2kg over 12 weeks) in sedentary subjects at maintenance calories, but these effects are substantially smaller than diet-driven weight loss. The peptide amplifies existing metabolic conditions — it doesn’t override thermodynamics or replace structured nutrition.

CJC-1295 with DAC includes a Drug Affinity Complex modification that binds to serum albumin, extending half-life to 6–8 days and allowing weekly dosing. CJC-1295 without DAC (often called Modified GRF 1-29) has a half-life under 30 minutes and requires multiple daily injections to maintain elevated GH levels. The DAC version produces sustained IGF-1 elevation; the no-DAC version creates acute GH pulses that subside within hours. For body recomposition research, the DAC form is preferred due to dosing convenience and stable hormone levels.

Research establishes a leucine threshold of 2.5–3g per meal to maximally stimulate muscle protein synthesis via mTOR activation, which typically requires 25–40g complete protein per feeding. For recomposition protocols using CJC-1295, total daily protein should reach 1.6–2.2g per kilogram bodyweight, distributed across 3–4 meals. Falling short of per-meal leucine thresholds undermines the anabolic environment CJC-1295 creates, reducing lean mass retention during deficits or blunting gains at maintenance.

The most frequently reported side effects are injection site reactions (redness, swelling at the subcutaneous injection site) and transient water retention, occurring in 15–25% of subjects in clinical trials. These effects are dose-dependent and typically resolve within 7–10 days of continued use. Rare adverse events include joint discomfort and transient hyperglycaemia at doses above 60mcg/kg weekly. Serious events like pituitary tumour growth are theoretical risks with chronic GH elevation but have not been documented in published CJC-1295 trials lasting up to 24 weeks.

Published human trials have evaluated CJC-1295 safety for up to 24 weeks without identifying cumulative toxicity or irreversible adverse effects. However, long-term data (beyond six months) in humans is limited. Theoretical concerns with chronic GH elevation include increased cancer risk in predisposed individuals and metabolic dysregulation, but these have not been observed in controlled trials. Most research protocols cycle CJC-1295 use (12–16 weeks on, 4–8 weeks off) to allow pituitary recovery and minimise unknown long-term risks.

CJC-1295 produces mean IGF-1 increases of 45–60% above baseline, whereas exogenous recombinant growth hormone can elevate IGF-1 by 200–300% or more. The recomposition effects are correspondingly smaller with CJC-1295 — clinical trials show 1–2kg lean mass gain versus 3–5kg with GH over similar timeframes. However, CJC-1295 works within physiological feedback loops, reducing the risk of insulin resistance, joint oedema, and other supraphysiological side effects common with exogenous GH. Cost is also substantially lower for peptide protocols.

Exposure to temperatures above 8°C causes irreversible protein denaturation in reconstituted peptides, rendering CJC-1295 inactive even if visual appearance remains unchanged. A single overnight temperature excursion at 20–25°C can destroy 40–60% of active peptide content within 12 hours, based on stability data for similar lyophilised compounds. Once denatured, potency cannot be restored by re-refrigeration. Proper storage requires consistent refrigeration at 2–8°C from the moment of reconstitution through final use.

CJC-1295’s anti-catabolic effects — mediated through elevated IGF-1 and growth hormone’s nitrogen-sparing action — help preserve lean mass during moderate deficits (10–20% below maintenance). Clinical data shows significantly less lean tissue loss in subjects using CJC-1295 during energy restriction compared to placebo, provided protein intake remains at 1.8–2.2g per kilogram bodyweight and resistance training continues. The peptide doesn’t eliminate muscle loss entirely during aggressive deficits (>25% restriction) but measurably reduces the rate.

True body recomposition — simultaneous fat loss and lean mass gain — often produces minimal scale weight change while body composition shifts measurably. If total bodyweight remains stable but waist circumference decreases and strength increases, recomposition is occurring as expected. Visible changes depend on starting body fat percentage; subjects above 20% body fat see clearer fat loss, while leaner individuals (12–15%) experience slower, subtler shifts. Absence of change after 10–12 weeks typically indicates inadequate protein intake, insufficient training stimulus, or caloric intake exceeding true maintenance.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA